Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, presented new data on Friday highlighting the impact of alterations in FBXW7, ...
Elevated sodium levels in tumors boost T-cell metabolic fitness and cytotoxicity, revealing potential avenues for improving ...
a preclinical Polθ ATPase inhibitor program; as well as additional, undisclosed preclinical programs. For more information, please visit reparerx.com and follow @Reparerx on X (formerly Twitter) and ...
A new process, nucleophagy, repairs damaged DNA that is particularly relevant for patients undergoing colorectal cancer ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and ...
In summary, these BLI data demonstrate that B. subtilis MinD is capable of binding membrane in both monomeric and dimeric form, while the presence of ATP in the binding pocket appears to affect both ...
An ATPase import motor is believed to provide the pulling force from the stromal side to drive the translocation of preproteins, which is essential for the development and biogenesis of chloroplasts.
Lucy Therapeutics Inc. has disclosed new mitochondrial F1F0 ATPase hydrolase inhibitors potentially useful for the treatment of cancer, acute coronary syndrome, ischemia, neurodegeneration and ...
Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts. Export articles to Mendeley Get article recommendations from ACS based on references in your ...
Using purified proteins, an ATPase-defective Cdc6 mutant ‘Cdc6-E224Q’ promoted MCM loading on DNA. Cdc6-E224Q also promoted MCM binding at origins in vivo but cells remained blocked in G1-phase. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback